Legal & General Group Plc Sells 2,227 Shares of Insmed Incorporated (NASDAQ:INSM)

Share on StockTwits

Legal & General Group Plc decreased its position in shares of Insmed Incorporated (NASDAQ:INSM) by 3.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,254 shares of the biopharmaceutical company’s stock after selling 2,227 shares during the period. Legal & General Group Plc owned approximately 0.06% of Insmed worth $870,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. NumerixS Investment Technologies Inc bought a new position in Insmed during the fourth quarter valued at $43,000. Great West Life Assurance Co. Can bought a new position in Insmed during the fourth quarter valued at $133,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Insmed by 16.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,771 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 953 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Insmed during the fourth quarter valued at $258,000. Finally, Proficio Capital Partners LLC bought a new position in Insmed during the first quarter valued at $200,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

A number of research firms have recently commented on INSM. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a report on Tuesday, May 5th. Zacks Investment Research cut shares of Insmed from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd. ValuEngine cut shares of Insmed from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 24th. Credit Suisse Group cut their price target on shares of Insmed from $49.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, March 17th. Finally, HC Wainwright restated a “buy” rating and issued a $52.00 price target on shares of Insmed in a report on Thursday, June 25th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Insmed presently has an average rating of “Buy” and an average price target of $40.44.

NASDAQ:INSM opened at $26.86 on Wednesday. Insmed Incorporated has a 1-year low of $12.09 and a 1-year high of $34.94. The company has a 50-day moving average of $26.36 and a 200 day moving average of $23.65. The firm has a market cap of $2.63 billion, a PE ratio of -9.52 and a beta of 2.72. The company has a debt-to-equity ratio of 1.74, a current ratio of 6.89 and a quick ratio of 6.46.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.02). The business had revenue of $36.90 million during the quarter, compared to analysts’ expectations of $34.81 million. Insmed had a negative return on equity of 87.35% and a negative net margin of 162.82%. The firm’s revenue was up 68.5% compared to the same quarter last year. During the same period last year, the company earned ($0.96) earnings per share. Sell-side analysts anticipate that Insmed Incorporated will post -2.78 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Article: How to invest in a bear market

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Whittier Trust Co. of Nevada Inc. Lowers Stock Holdings in Paychex, Inc.
Whittier Trust Co. of Nevada Inc. Lowers Stock Holdings in Paychex, Inc.
Diageo  Upgraded by Bryan, Garnier & Co to Buy
Diageo Upgraded by Bryan, Garnier & Co to Buy
Whittier Trust Co. of Nevada Inc. Has $817,000 Stock Position in Novo Nordisk A/S
Whittier Trust Co. of Nevada Inc. Has $817,000 Stock Position in Novo Nordisk A/S
Patriot Financial Group Insurance Agency LLC Reduces Stock Holdings in Vanguard Small-Cap Value ETF
Patriot Financial Group Insurance Agency LLC Reduces Stock Holdings in Vanguard Small-Cap Value ETF
State Street Corp Has $215.48 Million Holdings in Mohawk Industries, Inc.
State Street Corp Has $215.48 Million Holdings in Mohawk Industries, Inc.
APG Asset Management N.V. Has $4.85 Million Position in Signature Bank
APG Asset Management N.V. Has $4.85 Million Position in Signature Bank


© 2006-2020 Ticker Report